Response to Inhibition of Receptor‐Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo‐Controlled Study-Reference-Cited by-同舟云学术

Response to Inhibition of Receptor‐Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo‐Controlled Study

Published:2020-07-07 Issue:4 Volume:108 Page:808-816
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Weisel Kathleen¹,Berger Scott¹,Papp Kim²,Maari Catherine³,Krueger James G.⁴,Scott Nicola⁵,Tompson Debra⁵,Wang Susanne¹,Simeoni Monica⁶,Bertin John¹,Peter Tak Paul⁵

Affiliation:

1. GlaxoSmithKline Collegeville Pennsylvania USA

2. Probity Medical Research Waterloo Ontario Canada

3. InnovaDerm Research Montreal Quebec Canada

4. The Rockefeller University New York New York USA

5. GlaxoSmithKline Stevenage UK

6. GlaxoSmithKline Stockley Park UK

Funder

GlaxoSmithKline

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1852

Reference16 articles.

1. Early effects of tumour necrosis factor blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis

2. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response

3. Psoriasis Pathogenesis and Treatment

4. Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders - a review of the current literature and patents

5. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase I randomized study to evaluate safety, pharmacokinetics, and pharmacodynamics of SIR2446M, a selective RIPK1 inhibitor, in healthy participants;Clinical and Translational Science;2024-07

2. Sequential immunotherapy: towards cures for autoimmunity;Nature Reviews Drug Discovery;2024-06-05

3. Protein phosphorylation and kinases: Potential therapeutic targets in necroptosis;European Journal of Pharmacology;2024-05

4. Cell death as an architect of adult skin stem cell niches;Cell Death & Differentiation;2024-04-22

5. Saracatinib inhibits necroptosis and ameliorates psoriatic inflammation by targeting MLKL;Cell Death & Disease;2024-02-08